E
Sell
12/4/2023Downgrade
LSL Pharma Group Inc. (LSL.V) was downgraded to E+ from D- on 12/4/2023 due to a noticeable decline in the efficiency index, valuation index and solvency index. Debt to equity increased from 0.78 to 1.18, and the quick ratio declined from 0.19 to 0.12.
D
Sell
12/1/2023Upgraded
LSL Pharma Group Inc. (LSL.V) was upgraded to D- from E on 12/1/2023 due to a noticeable increase in the efficiency index, growth index and solvency index. Total capital increased 18.92% from $13.55M to $16.11M, earnings per share increased from -$0.0342 to -$0.028, and net income increased 13.66% from -$2.67M to -$2.31M.
E
Sell
9/1/2023Upgraded
LSL Pharma Group Inc. (LSL.V) was upgraded to E from E- on 9/1/2023 due to an increase in the volatility index.
E
Sell
7/7/2023None
LSL Pharma Group Inc. (LSL.V) was downgraded to E- from U on 07/07/2023.
